Clinical Trials in Romania

• Three-arm study of the clinical efficacy, safety and tolerability of ianalumab (VAY736) in patients with active Sjögren’s syndrome Ended
  2024-511068-10-00 Phase III Sjögren’s Syndrome Novartis Pharma AG
• Study of efficacy, safety and tolerability of ianalumab versus placebo, in combination with SoC therapy, in participants with active lupus n… Ended
  2023-508559-37-00 Phase III Lupus nephritis Novartis Pharma AG
• A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants ≥16 years of age with… Ended
  2024-511990-31-00 Phase III Fabry Disease Sanofi-Aventis Recherche & Developpement
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multiple Sclerosis Ended
  2023-505974-14-00 Phase III Multiple Sclerosis (MS) F. Hoffmann-La Roche AG
• A study to test whether different combinations of BI 765063, ezabenlimab, chemotherapy, cetuximab, and BI 836880 help people with head and n… Ended
  2024-512799-36-00 Phase I (Other) head and neck squamous cell carcinoma (HNSCC) Boehringer Ingelheim International GmbH
• A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects wi… Ended
  2024-513177-48-00 Phase II Chronic Hepatitis B Virus Infection Vir Biotechnology Inc.
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended
  2023-505635-13-00 Phase III Systemic lupus erythematosus Biogen Idec Research Limited
• A late stage clinical trial to investigate the efficacy and safety of Osimertinib versus Placebo in patients with stage IA2-IA3 non-small ce… Ended
  2023-509943-28-00 Phase III Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutat… AstraZeneca AB
• Study to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopeni… Ended
  2024-513147-90-00 Phase III Primary Immune Thrombocytopenia Argenx
• Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended
  2023-510097-14-00 Phase III Patients with MMR deficient relapse or advanced / metastatic… Arcagy Gineco
• Clinical Trial of MK-7684A with chemotherapy for extensive stage small cell lung cancer (ES-SCLC) Ended
  2023-503517-30-00 Phase III Extensive-stage small-cell lung cancer Merck Sharp & Dohme LLC
• Extension Study to Evaluate the Long-Term Outcomes of Paediatric Patients Who Received Treatment for Retinopathy of Prematurity in the VGFTe… Ended
  2024-513231-24-00 Phase III Retinopathy of prematurity (ROP) Regeneron Pharmaceuticals Inc.
• A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu… Ended
  2024-514619-88-00 Phase III Relapsing Multiple Sclerosis Immunic AG
• Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 Ended
  2024-516293-29-01 Phase II Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS)… Taiho Oncology Inc.
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended
  2023-503640-14-00 Phase III Newly diagnosed Philadelphia-negative B-cell precursor Acute… Amgen Inc.
• A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing-Remitting Mu… Ended
  2023-506516-40-00 Phase III Relapsing-Remitting Multiple Sclerosis F. Hoffmann-La Roche AG
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background N… Ended
  2023-505696-74-00 Phase III systemic lupus erythematosus Biogen Idec Research Limited
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended
  2023-509372-41-00 Phase III Multiple Sclerosis Novartis Pharma AG
• Long-term follow-up study to evaluate durability of treatment response in previous bepirovirsen study participants (B-Sure). Ended
  2023-506867-33-01 Phase II Chronic Hepatitis B Glaxosmithkline Research & Development Limited
• A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Ended
  2024-511599-33-00 Phase III Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Loxo Oncology Inc.
• A research study to compare different doses of a new investigational medicinal product for treatment of certain patients with Duchenne muscu… Ended
  2024-511492-15-00 Phase III Duchenne Muscular Dystrophy Sarepta Therapeutics Inc.
• A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRA… Ended
  2023-506241-30-00 Phase III Advanced Colorectal Cancer with KRAS G12C Mutation Mirati Therapeutics Inc.
• A clinical study to assess the efficacy of alpelisib plus fulvestrant in participants with HR-positive, HER2-negative, advanced breast cance… Ended
  2023-509133-39-00 Phase III Hormone receptor positive, HER2-negative advanced breast can… Novartis Pharma AG
• A research study to find out whether a medicine called inclisiran helps to prevent cardiovascular death, heart attacks or strokes in people … Ended
  2024-510735-21-00 Phase III Atherosclerotic cardiovascular disease (ASCVD) Novartis Pharma AG

Showing 529–552 of 865 trials